Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official regulatory information for Clarithro 500

Overdose Scope

Documented overdose presentations: Overdose of Clarithromycin is documented by the occurrence of severe gastrointestinal symptoms, including significant stomach pain, nausea, vomiting, and diarrhea.

Physiological systems affected (as stated in label): The systems principally affected are Gastrointestinal. Transient hearing loss has also been reported with very high doses, indicating a potential effect on the Auditory system.

Dose-related or exposure-related factors (if applicable): The primary documented risk factor is exposure to a massive acute ingestion.

Population-specific overdose notes (if applicable): No specific population-based differences in single-drug overdose severity are explicitly cited in official regulatory overdose summaries.

Emergency-response statements (as written in official documents): In case of any suspected overdose, immediate medical attention is required. Official guidance mandates that patients or caregivers call the poison control helpline for advice. Treatment protocols require the prompt elimination of unabsorbed drug and initiation of general supportive measures.

When immediate medical help is required (label-derived phrasing only): Immediately call emergency services (e.g., 911) if the affected person has serious, life-threatening manifestations such as collapse, experiencing a seizure, demonstrating trouble breathing, or being unable to be awakened (unresponsive).

Overdose classifications (high-level)

Severity classification (as defined in official documents): Regulatory guidance separates the common gastrointestinal overdose symptoms from the severe systemic outcomes (e.g., collapse, seizure) that mandate immediate, urgent medical intervention.

Regulatory basis (EMA / FDA / etc.): These statements are consistent with information published in official regulatory documents, including the U.S. FDA prescribing information and MedlinePlus.

Overdose-context constraints (as defined in official documents): Regulatory labels note that clarithromycin serum concentrations are not expected to be appreciably affected by hemodialysis or peritoneal dialysis, defining a procedural constraint on management.

Resulting overdose structure

Official overdose statements: • Overdose is primarily documented by severe gastrointestinal upset, encompassing abdominal pain, vomiting, and diarrhea. • Urgent contact with the poison control helpline is required for all suspected overdose situations. • Immediate contact with emergency services is mandated if life-threatening signs such as collapse, trouble breathing, or unresponsiveness are present. • Treatment is supportive and involves the prompt elimination of unabsorbed drug; hemodialysis is explicitly noted as ineffective for drug clearance.

Connection to the overall overdose profile (2–4 sentences): The official regulatory documents define the overdose profile by listing the expected initial clinical presentation, which centers on severe gastrointestinal upset. These documents then establish a clear protocol for seeking emergency medical care by identifying severe, systemic events as non-negotiable triggers for immediate contact with emergency services. This structure emphasizes mandatory patient actions and details the documented limitations of procedural interventions in overdose management.

Therapeutic Uses of Clarithro 500

Main Uses and Benefits of Clarithro 500

Clarithro 500 contains clarithromycin, a macrolide antibiotic designed to inhibit the growth of specific bacteria. It is primarily used to treat various types of bacterial infections by interfering with the protein synthesis necessary for bacteria to multiply.

Respiratory Tract Infections

Clarithro 500 is frequently used for infections affecting the upper and lower respiratory systems. These include:

Pharyngitis and Tonsillitis: Inflammation of the throat and tonsils caused by bacterial pathogens.
Sinusitis: Bacterial infection of the nasal sinuses.
Bronchitis: Acute bacterial exacerbations of chronic bronchitis.
Pneumonia: Community-acquired pneumonia caused by susceptible organisms.

Skin and Soft Tissue Infections

The medication is effective against uncomplicated skin and soft tissue infections. These conditions involve bacterial growth within the skin layers or the underlying tissue, often manifesting as localized redness, swelling, or pain.

Helicobacter pylori Eradication

In the context of gastrointestinal health, Clarithro 500 is used as part of a combination therapy to eliminate Helicobacter pylori (H. pylori). This bacterium is a significant factor in the development of duodenal ulcers. By reducing the bacterial load, the treatment helps facilitate the healing of the ulcer and reduces the risk of recurrence.

Mycobacterial Infections

Clarithro 500 is also utilized in the prevention and treatment of disseminated mycobacterial infections, particularly those caused by Mycobacterium avium complex (MAC). These infections are more common in individuals with compromised immune systems.

Key Benefits

Broad-Spectrum Activity: It targets a wide variety of Gram-positive and some Gram-negative aerobic and anaerobic bacteria.
Targeted Action: By focusing on bacterial protein synthesis, it helps the body's immune system clear the infection more effectively.
Tissue Penetration: The active ingredient achieves high concentrations in specific body tissues, particularly in the lungs and respiratory tract, which supports its efficacy in treating localized infections.

Regulatory References

NIH DailyMed drug label overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Clarithro 500 (Clarithromycin)

Clarithro 500 (clarithromycin) eligibility is defined by strict regulatory guidelines regarding age, organ function, and pre-existing medical conditions. The tablet formulation is primarily intended for adults and adolescents 12 years of age and older. Use in children under 12 is not recommended; pediatric liquid formulations are required for this age group.

Populations That Must Not Use Clarithro 500 (Contraindications)

Use is absolutely prohibited (contraindicated) for the following groups, as stated in official labeling:

Patients with a known hypersensitivity or allergy to clarithromycin, erythromycin, or any macrolide antibiotic.
Patients with a history of QT prolongation or ventricular cardiac arrhythmia.
Patients with uncorrected low potassium or magnesium levels.
Patients with concurrent severe hepatic failure and renal impairment.

Populations Requiring Caution or Restriction

Caution is required for patients with isolated impaired hepatic function and for those with moderate to severe renal impairment, which may necessitate a lower dose. The medicine is generally not recommended during pregnancy (especially the first trimester) and lactation, as its safety for the fetus or breastfed infant is not fully established by regulatory bodies.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Clarithro 500 (Clarithromycin) is a potent inhibitor of the Cytochrome P450 3A4 (CYP3A4) enzyme, which is the primary driver of its complex drug interaction profile as documented in regulatory labeling.

Contraindicated Combinations

Co-administration with Clarithromycin is strictly forbidden for certain medicines due to the high risk of severe, life-threatening events:

Statins: Lovastatin and Simvastatin (due to increased risk of myopathy/rhabdomyolysis).
Cardiac/Antiarrhythmics: Pimozide, Cisapride, Astemizole, and Terfenadine (due to risk of severe cardiac arrhythmias and QT prolongation).
Ergot Alkaloids: Ergotamine and Dihydroergotamine (due to risk of acute ergot toxicity/vasospasm).
Colchicine (contraindicated in patients with renal or hepatic impairment).

Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type	Affected Product/Class	Required Action in Label
CYP3A4 Substrate Increase	Digoxin, Midazolam (Oral), Warfarin, Calcineurin Inhibitors	Close monitoring and dose adjustment may be required.
Loss of Clarithromycin Efficacy	CYP3A4 Inducers (e.g., Rifampicin, Efavirenz)	Avoidance or alternative therapy may be necessary due to sub-therapeutic levels.
Additive Cardiotoxicity	Other QT-Prolonging Drugs (e.g., Ranolazine, Ticagrelor)	Contraindicated or use with extreme caution and monitoring.

Administration and Population Notes

The extended-release formulation must be taken with food as noted in administration guidelines to prevent reduced bioavailability.
Interaction risks, particularly for Colchicine and general toxicity, are heightened in patients with hepatic or renal impairment, necessitating careful review of official constraints.

Mechanism of Action

Targeting the Bacterial Protein Factory

Clarithromycin acts through a highly specific molecular mechanism: it forms a reversible bond with the 23S ribosomal RNA of the bacterial 50S ribosomal subunit, physically blocking the process of translocation. This action immediately halts the bacteria's ability to manufacture essential proteins, resulting in the physiological effect of bacteriostasis (stoppage of growth) and a corresponding arrest of pathogen population dynamics.

Synergy and Host Modulatory Effects

The drug's mechanism is enhanced by its active metabolite, 14-hydroxyclarithromycin, which retains the same inhibitory action, works complementarily against the bacterial target. Furthermore, Clarithromycin exerts a secondary immunomodulatory action by influencing host inflammatory pathways, such as the release of certain cytokines. This dual cascade—antimicrobial inhibition plus inflammation modulation—influences the systemic physiological changes resulting from the mechanism.

️ Limitations of the Ribosomal Mechanism

The effectiveness of this ribosomal mechanism can be constrained by bacterial resistance. This occurs primarily through enzymatic methylation of the 23S rRNA binding site, which prevents the drug from docking effectively. Alternatively, bacterial efflux pumps may actively transport the Clarithromycin molecule out of the cell, functionally limiting the concentration required for ribosomal inhibition.

Dosage and Administration Information

Clarithromycin, the active ingredient in Clarithro 500, is administered through the Oral route using tablets or suspension, or via Intravenous (IV) Infusion for severe initial treatment.

Official Dosing Regimens and Frequency

The standard adult dose for the Immediate-Release (IR) tablet is typically 250 mg to 500 mg taken twice daily (every 12 hours). For Extended-Release (ER) tablets, the regimen is usually 1000 mg taken once daily. In certain combination regimens, such as those for H. pylori eradication, the dose may be 500 mg two or three times daily.

Administration Conditions and Duration

Instruction Domain	Official Requirement
Timing to Meals	IR tablets/suspension may be given with or without food. ER tablets must be taken with food.
Tablet Integrity	Extended-Release tablets must be swallowed whole and not crushed or chewed.
Course Duration	The usual duration is 6 to 14 days for most acute conditions, but treatment may be long-term for specific Mycobacterial infections.

Population-Specific Use

For pediatric patients under 12 years of age, the use of tablets is not recommended; instead, an oral suspension is used based on body weight. For adults with severe renal impairment (Creatinine Clearance < 30 mL/min), the dose of clarithromycin must be reduced by half. If a dose is missed, it should be taken as soon as possible, but double doses must not be taken to compensate. The IV administration is typically limited to a short period (e.g., 2–5 days) before switching to oral therapy.

Connection to the Overall Use Protocol

The instructions establish a precise protocol by defining fixed dose amounts, setting clear administration frequencies, and specifying mandatory conditions (such as food requirement for the extended-release form or dose reduction in renal impairment). This framework ensures the medicine is used according to established standards for the specified duration.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research on Monotherapy

Studies have explored whether the drug was evaluated as a therapeutic strategy for certain conditions. Research assessed outcomes related to the severity and frequency of symptoms in adults over a period of 12 weeks.

Primary Efficacy Studies

Several double-blind, randomized, placebo-controlled trials (RCTs) measured the difference in reported symptom profiles compared to a placebo group. Research also examined long-term follow-up measurements over a 6-month period, which assessed whether initial results were maintained.

Side Effect Profile

Clinical trials monitored for adverse events across different patient groups. Common adverse events observed in the studies included mild headache and temporary nausea. Less common, but monitored, events involved transient changes in laboratory markers.

Combination Therapy Evaluations

Research evaluated the potential for a complementary action when the drug was used alongside a standard first-line treatment, particularly in areas like H. pylori eradication and certain respiratory infections.

Combination Action Assessment

Findings assessed symptom load measurement differences when used in combination compared to the standard treatment alone. One focus was on the relationship between the drug's activity and that of other agents in multi-drug regimens.

Speed of Response Measurement

Specific trials investigated the onset of measured response, evaluating the time to the first documented change when the drug was added to a participant's existing regimen.

Special Populations and Long-Term Use

Studies have been conducted to determine the drug's potential contribution to the study objectives in older adults (age 65 and above). Research evaluated measurements of inflammation markers in this demographic. Research also addressed questions related to the safety profile during long-term use.

Key Studies & References

Clarithromycin for Eradication of Helicobacter pylori: A Systematic Review and Meta-Analysis of Combination Regimens

Frequently Asked Questions (FAQ)

Common questions about Clarithro 500 (FAQ)

Q: Is Clarithro 500 the same as Azithromycin?

A: Clarithromycin (Clarithro 500) and Azithromycin are both classified as macrolide antibiotics, but they are different medicines. While they share a similar mechanism of action, official product information indicates they have different chemical structures, can be prescribed for different lengths of time, and carry unique lists of possible drug interactions.

Q: What's the difference between Clarithro 500 and Amoxicillin?

A: Clarithromycin belongs to the macrolide class of antibiotics, while Amoxicillin is a penicillin-class antibiotic. Official guidance notes that these drugs work differently against bacteria and are used to treat different types of susceptible infections. Clarithromycin is often used as an alternative for people who have a known allergy to penicillin-based therapies.

Q: Are there any long-term side effects associated with Clarithro 500?

A: Studies and official drug safety communications have identified a potential increased risk of heart problems or death in patients with established coronary heart disease (CHD). This risk may occur years after completing the short course of treatment. Regulatory documents state that prescribers should consider the benefit-risk in CHD patients and may consider alternative antibiotics.

Q: What happens if you stop taking Clarithro 500 too early?

A: Official guidelines recommend that the full prescribed duration of the medicine is completed. Stopping an antibiotic course early may prevent the infection from clearing entirely. This practice can also contribute to the development of bacterial resistance.

Q: Can children take Clarithro 500, and is the dosage different?

A: Clarithro 500 tablets are generally not recommended for children under 12 years of age. For pediatric patients, an oral suspension (liquid) form is used instead. The dosage for the suspension is determined by the child’s body weight, as outlined in the official prescribing information.

Q: Is Clarithro 500 safe to use during pregnancy?

A: Official labeling states that this medicine is generally not recommended for use during pregnancy, especially during the first trimester. The medicine is typically only used if no appropriate alternative treatments are available and the treating healthcare professional determines the potential benefit outweighs the potential risk to the fetus.

Q: Why is Clarithro 500 often mentioned in treating H. pylori?

A: The official indications include the use of Clarithromycin in combination with other drugs for the specific purpose of eradicating H. pylori infection. This combination therapy is essential to help treat and prevent the recurrence of ulcers caused by this bacterium.

Q: Can Clarithro 500 be used for a dental infection?

A: Clarithromycin is an antibiotic indicated for infections caused by susceptible organisms, including certain respiratory and skin infections. While it may be used in specific circumstances, it is not typically a first-line treatment for all common dental infections.

Q: Is Clarithro 500 effective for strep throat?

A: Yes, official prescribing information indicates that Clarithromycin tablets are used to treat certain mild to moderate infections caused by the bacteria Streptococcus pyogenes (which causes strep throat). It is often prescribed as an alternative for people who are allergic to penicillin-based therapies.

Q: Can taking Clarithro 500 affect sleep?

A: Yes, insomnia (difficulty sleeping) is listed in the official safety data as a common side effect of Clarithromycin.

Q: Does Clarithro 500 interact with birth control pills?

A: Official information generally does not list a direct interaction where Clarithromycin stops hormonal birth control from working. However, if the antibiotic causes severe side effects like vomiting or diarrhea, the effectiveness of the contraceptive pill may be reduced due to poor absorption.

Q: What are the signs of an allergic reaction to Clarithro 500?

A: Signs of a serious allergic reaction, as documented in regulatory warnings, include rash, itching, hoarseness, trouble breathing or swallowing, or swelling of the face, hands, or throat. Serious skin reactions, such as Stevens-Johnson Syndrome, have been reported in the post-marketing setting.

Q: Is it normal to feel tired while taking Clarithro 500?

A: While general tiredness is not listed as a common side effect, official warnings note that unusual weakness or tiredness can be a potential symptom of a more serious adverse reaction, such as a liver problem. If concerning symptoms, such as dark urine or yellowing of the skin, occur, it is important to seek guidance from a healthcare professional.

Q: What kind of research has been done on the long-term effectiveness of Clarithro 500?

A: Long-term follow-up research has been conducted, notably a 10-year study that tracked patients from a previous clinical trial. This research identified an unexpected increase in death and heart problems years after a two-week course of clarithromycin in patients with pre-existing coronary heart disease.

Q: Can people with diabetes safely use Clarithro 500?

A: Official warnings indicate that using Clarithromycin alongside certain diabetes medications (like sulfonylureas) or insulin can result in significant low blood sugar (hypoglycemia). Patients who use this medication concurrently with insulin or oral diabetes treatments may require close monitoring of blood glucose levels.

Q: Is a bitter taste the most common complaint with Clarithro 500?

A: Dysgeusia (taste perversion) is listed in the official clinical trial data as a Very Common side effect, alongside abdominal pain, diarrhea, nausea, and vomiting.

Q: Why do some people feel dizzy or lightheaded on Clarithro 500?

A: Dizziness is listed in the regulatory documents as an uncommon side effect. It can also, in rare but serious cases, be a symptom related to changes in the heart's rhythm, which can cause lightheadedness or fainting.

Q: Is there a liquid form of Clarithro 500 available?

A: Yes. While Clarithro 500 refers to the tablet strength, the medicine (Clarithromycin) is also available as an oral suspension (liquid). The liquid form is primarily used for children or for individuals who have difficulty swallowing tablets.

Q: What is the role of the 500mg dosage in treatment?

A: The 500 mg strength is one of the standard doses for adults and adolescents 12 years and older. It is used for the treatment of various bacterial infections and is also part of specific combination therapies, such as those prescribed for H. pylori eradication.

Q: Why is Clarithro 500 sometimes used to treat skin infections?

A: Official labeling indicates that Clarithromycin is used for the treatment of mild to moderate uncomplicated skin and skin structure infections. These are caused by specific bacteria that are known to be susceptible to the macrolide class of antibiotics.

Q: Can Clarithro 500 be used for bronchitis or pneumonia?

A: Yes. Official indications for Clarithromycin tablets include the treatment of acute bacterial exacerbation of Chronic Bronchitis in adults and Community-Acquired Pneumonia, when caused by susceptible bacteria.

Q: Does Clarithro 500 work against viral infections?

A: No. Clarithromycin is an antibiotic designed to fight bacteria by stopping protein production. It will not work against infections caused by viruses, such as the common cold or the flu.

Q: Is it possible to become resistant to Clarithro 500 over time?

A: Yes, bacteria can develop resistance to Clarithromycin. Official documents note that this is a known risk with macrolide antibiotics. Using an antibiotic when it is not needed or stopping a course early can contribute to the development of bacterial resistance.

Q: Can Clarithro 500 cause yeast infections?

A: Official safety information notes that, like many antibiotics, Clarithromycin can disrupt the natural balance of microorganisms in the body. This disruption may increase the likelihood of an overgrowth of Candida fungus, which can lead to a yeast infection (thrush).

Q: How long does Clarithro 500 stay in your system after the last dose?

A: Pharmacokinetic studies show that Clarithromycin has an elimination half-life typically ranging from about 2.3 to 6.0 hours. This means the time it takes for the drug to be largely cleared from the system varies based on the individual and the dosage form used.

Q: What should be avoided in the diet while taking Clarithro 500?

A: The extended-release tablet form of Clarithromycin must be taken with food to ensure the medicine is properly absorbed. There are no other general food restrictions listed in the regulatory documents, though it must not be taken with certain contraindicated medicines.

Q: Does Clarithro 500 interact with alcohol?

A: Official regulatory documents do not list a significant or specific interaction where alcohol directly reduces the effectiveness of Clarithromycin. However, avoiding alcohol is generally recommended when recovering from an infection or illness, as it may interfere with the healing process.

Q: Is it normal for my urine to change color while on Clarithro 500?

A: Official safety data lists dark urine as a potential symptom of a rare but serious liver problem. If this color change occurs, especially along with yellowing of the skin or eyes (jaundice) or upper abdominal pain, it is important to seek guidance from a healthcare professional.

How should Clarithro 500 be stored and disposed of?

Storage and Disposal of Clarithro 500

The storage of Clarithro 500 (Clarithromycin 500 mg tablets) is governed by official regulatory standards to maintain product integrity. The tablets must be stored at controlled room temperature, typically 20 C to 25 C. It is mandatory to keep the container tightly closed in a dry place and to protect the medication from excess heat, moisture, and direct light. The tablets must not be frozen.

Official Requirements

Domain	Regulatory Instruction
Child Safety	Keep out of the reach and sight of children.
Disposal	Dispose of unused or expired product according to local requirements; do not discard in household trash or wastewater.

These conditions ensure the stability of the medicine until its expiration date.

Property	Description
Active ingredient	Clarithromycin
Form	Oral Tablet (500 mg strength)
Pharmacological class	Macrolide Antibiotic
Common use	Combats bacterial infections
Origin	Semi-synthetic (derived from Erythromycin)

Classification	Examples of Reactions
Very Common (ge 1/10)	Dysgeusia (taste perversion).
Common (ge 1/100 to < 1/10)	Diarrhea, nausea, vomiting, abdominal pain, headache, insomnia.
Uncommon (ge 1/1,000 to < 1/100)	Hypersensitivity, ECG QT prolonged, cholestasis, rash, dizziness, leukopenia.
Not Known (Cannot be estimated)	Torsades de pointes, fatal hepatic failure, Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), Pseudomembranous colitis.

Clarithro 500